Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.64 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.62 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.62 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 6/20 | 0.60 |
| ▸ | MITF | O75030 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10195728 | 1.00 | HSD17B10 (0.68) | HSD17B10ACKR3ABCG2MCHR2MCHR1 | |
| SCHEMBL10195730 | 1.00 | HSD17B10 (0.68) | HSD17B10ACKR3ABCG2MCHR2MCHR1 | |
| SCHEMBL18779410 | 0.93 | HSD17B10 (0.61) | HSD17B10ACKR3ABCG2MCHR2MCHR1 | |
| SCHEMBL4283979 | 0.88 | HSD17B10 (0.70) | HSD17B10ABCG2MCHR2MCHR1DRD2 | |
| SCHEMBL11919266 | 0.88 | DRD2 (0.67) | HSD17B10ABCG2MCHR2MCHR1DRD2 | |
| SCHEMBL9367355 | 0.88 | HSD17B10 (0.67) | HSD17B10ABCG2MCHR2MCHR1DRD2 | |
| SCHEMBL4341169 | 0.88 | MCHR1 (0.69) | HSD17B10ABCG2MCHR2MCHR1DRD2 | |
| SCHEMBL15317635 | 0.87 | HSD17B10 (0.65) | HSD17B10ABCG2MCHR2MCHR1DRD2 | |
| SCHEMBL11916163 | 0.87 | HSD17B10 (0.65) | HSD17B10ABCG2MCHR2MCHR1DRD2 | |
| SCHEMBL15317637 | 0.87 | HSD17B10 (0.65) | HSD17B10ABCG2MCHR2MCHR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3210609-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| EP-2655357-B1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO SA (CH) | 2016-06-22 | — | — | EP | disclosed |
| US-9273077-B2 | Phosphorus derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-9012462-B2 | Phosphorous derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8912330-B2 | Azaindole derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20140364423-A1 | Pyrazinopyrazines and Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. | 2014-12-11 | — | — | US | disclosed |
| US-8846664-B2 | Pyrazinopyrazines and derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-8354531-B2 | Compounds for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-15 | — | — | US | disclosed |
| WO-2012084704-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO S.A. (CH) | 2012-06-28 | — | — | WO | disclosed |
| US-20110294806-A1 | AZAINDOLE DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20100197656-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| US-7723341-B2 | Dihydrothienopyrimidines, suitable for the treatment of respiratory, gastrointestinal, inflammatory, nervous system disorders and/or cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2010-05-25 | — | — | US | disclosed |
| US-20100041662-A1 | Heterocyclic compounds as antiinflammatory agents | FERRAND SANDRINE | 2010-02-18 | — | — | US | disclosed |
| US-20100041662-A1 | Heterocyclic compounds as antiinflammatory agents | FERRAND SANDRINE | 2010-02-18 | — | — | US | disclosed |
| US-20090186875-A1 | Dihydrothienopyrimidines, suitable for the treatment of respiratory, gastrointestinal, inflammatory, nervous system disorders and/or cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186875-A1 | Dihydrothienopyrimidines, suitable for the treatment of respiratory, gastrointestinal, inflammatory, nervous system disorders and/or cancer | DPYD, DHODH, FH | HSD17B10 717/4885ACKR3 1037/4885ABCG2 582/4885 |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | HSD17B10 3173/4885ACKR3 2905/4885ABCG2 1069/4885 |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | HSD17B10 3309/4885ACKR3 2918/4885ABCG2 1335/4885 |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | HSD17B10 3425/4885ACKR3 2544/4885ABCG2 1284/4885 |
| US-20140364423-A1 | Pyrazinopyrazines and Derivatives as Kinase Inhibitors | MAP3K5, MAP3K15, MAP4K2 | HSD17B10 3283/4885ACKR3 1990/4885ABCG2 710/4885 |
| US-20110294806-A1 | AZAINDOLE DERIVATIVES AS KINASE INHIBITORS | ABL1, CDKN1A, MAP3K13 | HSD17B10 3069/4885ACKR3 2003/4885ABCG2 2027/4885 |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | HSD17B10 3173/4885ACKR3 2905/4885ABCG2 1069/4885 |
| US-20100197656-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | TPMT, MALT1, IL1B | HSD17B10 834/4885ACKR3 546/4885ABCG2 379/4885 |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | HSD17B10 3173/4885ACKR3 2905/4885ABCG2 1069/4885 |
| US-20100041662-A1 | Heterocyclic compounds as antiinflammatory agents | JAK2, IRAK4, ALK | HSD17B10 2698/4885ACKR3 120/4885ABCG2 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.